Anna Carnes-Vendrell

Dr. Anna Carnes-Vendrell

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2023 in GeroScience
Verified
Journal Article
Open access
PDF file
FDFarida Dakterzada
Farida Dakterzada
MFMariona Jove Font
Mariona Jove Font
RHRaquel Huerto
Raquel Huerto
ACAnna Carnes-Vendrell
Anna Carnes-Vendrell
JSJoaquim Sol
Joaquim Sol
GPGerard Piñol-Ripoll
Gerard Piñol-Ripoll
Genetic, metabolic, and clinical evidence links lipid dysregulation to an increased risk of Alzheimer’s disease (AD). However, the role of lipids in the pathophysiological processes of AD and its clinical progression is unclear. We investigated the association between cerebrospinal fluid (CSF) lipidome and the pathological hallmarks of AD, progression from mild cognitive impairment (MCI) to AD, and the rate of cognitive decline in MCI patients. The CSF lipidome was analyzed by liquid chromatography coupled to mass spectrometry in an LC-ESI-QTOF-MS/MS platform for 209 participants: 91 AD, 92 MCI, and 26 control participants. The MCI patients were followed up for a median of 58 (± 12.5) months to evaluate their clinical progression to AD. Forty-eight (52.2%) MCI patients progressed to AD during follow-up. We found that higher CSF levels of hexacosanoic acid and ceramide Cer(d38:4) were associated with an increased risk of amyloid beta 42 (Aβ42) positivity in CSF, while levels of phosphatidylethanolamine PE(40:0) were associated with a reduced risk. Higher CSF levels of sphingomyelin SM(30:1) were positively associated with pathological levels of phosphorylated tau in CSF. Cholesteryl ester CE(11D3:1) and an unknown lipid were recognized as the most associated lipid species with MCI to AD progression. Furthermore, TG(O-52:2) was identified as the lipid most strongly associated with the rate of progression. Our results indicate the involvement of membrane and intracellular neutral lipids in the pathophysiological processes of AD and the progression from MCI to AD dementia. Therefore, CSF neutral lipids can be used as potential prognostic markers for AD.

1 January 2023 in Aging and disease
Verified
Journal Article
Open access
PDF file
FDFarida Dakterzada
Farida Dakterzada
MFMariona Jove Font
Mariona Jove Font
RHRaquel Huerto
Raquel Huerto
ACAnna Carnes-Vendrell
Anna Carnes-Vendrell
JSJoaquim Sol
Joaquim Sol
GPGerard Piñol-Ripoll
Gerard Piñol-Ripoll
Aberrant lipid metabolism has been strongly linked to Alzheimer’s disease (AD) pathogenesis. However, the role of lipids in the pathophysiological processes of AD and their clinical progression is unclear. We hypothesized that plasma lipids are associated with the pathological hallmarks of AD, progression from mild cognitive impairment (MCI) to AD, and the rate of cognitive decline in MCI patients. To evaluate our hypotheses, we analysed the plasma lipidome profile by liquid chromatography coupled to mass spectrometry in an LC-ESI-QTOF-MS/MS platform for 213 subjects recruited consecutively: 104 AD, 89 MCI, and 20 control subjects. Forty-seven (52.8%) MCI patients progressed to AD during follow-up (58 ± 12.5 months). We found that higher plasma levels of sphingomyelin SM(36:0) and diglyceride DG(44:3) were associated with an increased risk of amyloid beta 42 (Aβ42) positivity in CSF, while levels of SM(40:1) were associated with a reduced risk. Higher plasma levels of ether-linked triglyceride TG(O-60:10) were negatively associated with pathological levels of phosphorylated tau in CSF. Plasma levels of fatty acid ester of hydroxy fatty acid FAHFA(34:0) and ether-linked phosphatidylcholine PC(O-36:1) were positively associated with pathological levels of total tau in CSF. Regarding the plasma lipids most associated with progression from MCI to AD, our analysis detected phosphatidyl-ethanolamine plasmalogen PE(P-36:4), TG(59:12), TG(46:0), and TG(O-62:7). Furthermore, TG(O-62:7) was the lipid that was most strongly associated with the rate of progression. In conclusion, our results indicate that neutral and ether-linked lipids are involved in the pathophysiological processes of AD and the progression from MCI to AD dementia, suggesting the involvement of lipid-mediated antioxidant mechanisms in AD.

1 January 2016 in Revista De Neurologia
Verified
Journal Article
Open access
ACAnna Carnes-Vendrell
Anna Carnes-Vendrell
JYJoan Deus Yela
Joan Deus Yela
JSJessica Molina Seguin
Jessica Molina Seguin
JPJosep Pifarré Paredero
Josep Pifarré Paredero
Francisco PurroyFrancisco Purroy
Francisco Purroy

26 November 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
BCBrenda Chino
Brenda Chino
LTLucía Torres-Simón
Lucía Torres-Simón
AŻAgnieszka Żelwetro
Agnieszka Żelwetro
IRInmaculada Concepción Rodríguez-Rojo
Inmaculada Concepción Rodríguez-Rojo
ACAnna Carnes-Vendrell
Anna Carnes-Vendrell
FMFernando Maestú
Fernando Maestú
Background: This study aimed to explore the association between a verbal learning task that evaluates the potential mutual dependency between memory and executive functions (i.e., the Test of Memory Strategies, TMS) and cerebrospinal fluid (CSF) Alzheimer’s Disease (AD) biomarkers. Methods: A sample of 47 mild cognitive impairment (MCI) participants from Poland and Spain were classified according to the Erlangen Score Diagnostic Algorithm (ESA) into CSF- (n = 16) and CSF+ (n = 31) groups. Correlation analyses between TMS word-list conditions and CSF biomarkers were conducted. Additionally, an analysis of covariance was performed to define the effect on ESA classification in the sample, using as a covariable the country of origin of the participants. Results: Significant associations between the TMS-3 condition and Aβ42, t-tau, and p-tau were observed for the whole sample. In addition, the CSF- participants obtained higher cognitive performance in TMS-3 compared to the CSF+ group. This outcome persisted if the groups were based on Aβ42 scores, but not t-tau or p-tau values. Conclusions: These findings could indicate that poor performance on verbal learning tests may be affected by executive dysfunctions. Therefore, future intervention plans focused on training executive functions would be of interest to improve the ability of MCI patients to encode and organize information.

10 April 2025 in Frontiers in Psychology
Verified
Journal Article
Open access
PDF file
BLBeatriz Lara-Consuegra
Beatriz Lara-Consuegra
ACAnna Carnes-Vendrell
Anna Carnes-Vendrell
PTPaula Torres-Hidalgo
Paula Torres-Hidalgo
GPGerard Piñol-Ripoll
Gerard Piñol-Ripoll
To date, the impact of cognitive therapies on patients with dementia and mild cognitive impairment (MCI) has been studied in terms of cognition, quality of life and activities of daily living rather than in the context of neuropsychiatric symptoms (NPS). The objective of this scoping review was to collect evidence that different cognitive therapies affect the NPS of patients with MCI and dementia. A bibliographic search was conducted in the PUBMED, EMBASE, ISI WOS and SCOPUS databases through February 2025. After the elimination of duplicates, a total of 1,854 publications were identified. Among these, 42 articles were included in the analysis. These articles were reviewed by title and abstract, and then the full text was reviewed by two independent researchers with subsequent decisions about conflicts made in consultation with a third researcher. A sample of 4,089 participants was collected. All participants had undergone cognitive training interventions, cognitive rehabilitation, cognitive stimulation, art therapy, reminiscence therapy or psychobehavioural therapy and were evaluated for NPS. Depression was the most commonly analysed symptom (70% of the articles). The types of interventions that improved NPS the most were art therapy and reminiscence therapy (76 and 71% of the articles), whereas cognitive training (43%) was the least effective. While all types of therapy seemed to support the improvement of NPS, art therapy and reminiscence therapy were the most effective, especially for patients with MCI or dementia. However, studies that comprehensively evaluate the effects of cognitive therapy on NPS other than depression are lacking.

1 December 2014 in Endocrinología y Nutrición
Verified
Journal Article
Closed access
ACAnna Carnes-Vendrell
Anna Carnes-Vendrell
AAAntonio Alcántara
Antonio Alcántara
MBMarta Bueno
Marta Bueno
ECEster Castan
Ester Castan
Albert LecubeAlbert Lecube
Albert Lecube